Q-omics provides the consensus-scored RPL7AP11 profile across patient tissues and cancer cell-line models. RPL7AP11 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPL7AP11 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, RPL7AP11 RNA expression shows 20,613 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, KIRC, and LSCC as cancer lineages where RPL7AP11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL7AP11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL7AP11 survival associations across molecular data types. RPL7AP11 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL7AP11 RNA expression–survival associations across cancer types. High RPL7AP11 expression shows unfavorable associations in ACC, PAAD, OV, KIRP and COAD, but favorable associations in MESO. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPL7AP11 RNA expression.
This table summarizes RPL7AP11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL7AP11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL7AP11 shows lower tumor expression in PAAD and higher tumor expression in KIRC, LIHC, COAD, THCA and KIRP. The KIRC box plot shows higher RPL7AP11 RNA expression in tumor versus normal tissue (log2 FC = +0.286, t-test p < 0.001).
This table shows molecular features associated with RPL7AP11 in patient tissues and cancer cell lines. In patient samples, RPL7AP11 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
